Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Genmab reported a strong first half of 2026 and raised guidance, with top-line momentum driven primarily by DARZALEX and also EPKINLY. Key Q4 catalysts include a prespecified interim readout for EPKINLY plus R-CHOP in frontline DLBCL and the accelerated Phase III Rina-S readout in platinum-resistant ovarian cancer, which could position Genmab as first-in-class among next-generation folate receptor-alpha ADCs.

Analysis

GMAB’s near-term valuation is increasingly a two-asset probability-weighted exercise rather than a royalty-growth story. A positive frontline lymphoma result would expand EPKINLY from later-line use into a much larger treatment pool, but the commercial value will depend on whether efficacy is sufficiently differentiated to overcome physician inertia around curative-intent R-CHOP and the incremental safety/administration burden of a bispecific. The relevant read-through is negative for Roche’s lymphoma franchise only at the margin; GMAB’s more direct upside is a higher terminal-growth multiple if frontline adoption appears feasible.

The ovarian catalyst has greater strategic importance than its headline market size suggests: a credible efficacy/safety advantage versus AbbVie’s ELREXFIO? No—AbbVie’s ELAHERE is the relevant FR-alpha benchmark—would validate GMAB’s ADC platform and reduce investor concern that the company remains overly dependent on DARZALEX-linked economics. Conversely, merely statistically positive data without a clinically persuasive PFS, durability, and discontinuation profile is unlikely to support a first-in-class valuation premium. For the next 1-3 months, abstract timing, trial-event maturity, and options-implied volatility will matter more than underlying earnings revisions.

Consensus may be underestimating correlation between the two readouts: simultaneous success would shift GMAB from a mature-royalty multiple toward a pipeline-platform multiple, while a miss in either can expose concentration risk in the royalty base. The asymmetric risk is that pre-event optimism prices in success before efficacy details are available; management’s timetable is not independent validation. Key falsifiers are frontline PFS/OS trend and cytokine-release/infection discontinuation rates for EPKINLY, plus ovarian PFS hazard ratio, overall-survival maturity, and treatment-emergent discontinuations relative with ELAHERE.

Key Decisions for Investors

• Maintain GMAB as a watch-list catalyst long rather than adding aggressively before efficacy details; initiate only after abstracts/results show clinically meaningful separation, with an initial 2-3% NAV risk budget and a 3-6 month horizon.
• For event exposure, prefer a defined-risk GMAB call spread expiring after the Q4 readouts over outright calls; size premium at risk to a full loss because two binary trials can create a 15-25% gap in either direction. Do not enter until option-implied move is compared with historical GMAB post-data moves.
• Set a post-result long GMAB / short ABBV exploratory pair only if the ovarian dataset shows superior durability with manageable discontinuations versus ELAHERE; use a 1:1 beta-adjusted structure over 3-6 months, and exit if regulatory positioning does not indicate a differentiated label path.
• Monitor JNJ guidance and DARZALEX royalty trajectory as the downside hedge on pipeline volatility: any material reduction in DARZALEX growth expectations would remove the cash-flow support for holding GMAB through a mixed or negative clinical outcome.